Ben Derman (@bdermanmd)

B

Ben Derman@bdermanmd · Jul 21

3/ @CanerSaygin on an excellent paper on the evolution of therapy-related CH in patients treated with or without lenalidomide: x.com/CanerSaygin/st…

CCaner Saygin, MD@CanerSaygin · Jul 16

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. nature.com/articles/s4137…

1

3

9

2

1.0K

Ben Derman Retweeted

C

Caner Saygin, MD@CanerSaygin · Jul 16

Very excited to share our paper investigating the evolution of therapy-related CH in myeloma pts treated w/ or w/o LEN. Can we predict the risk for second blood cancer in myeloma pts? Grateful for the collaboration with @UCCancerCenter myeloma program. nature.com/articles/s4137…

8

23

81

17

7.0K

Ben Derman Retweeted

U

UChicagoCancerCenter@UCCancerCenter · Jul 16

🔥 Hot off the press: In a new study, Cooperrider et al., show that lenalidomide drives expansion of high-risk TP53-mutant clones, which may predispose MM patients to secondary blood cancers like t-MDS and t-ALL. @CanerSaygin ⁦ @bdermanmd @UChicagoHemOnc ow.ly/gvMO50WqIjj

0

8

31

8

2.0K

B

Ben Derman@bdermanmd · Jul 15

Tune in to hear about MRD-directed decision making, CAR T updates, and TRIspecific antibodies!

cchadi nabhan MD, MBA, FACP@chadinabhan · Jul 15

What are the newest advances in myeloma? ⁦@bdermanmd⁩ joins my #HealthcareUnfiltered podcast to share latest date from #ASCO25 & #EHA25. Here’s a link to the full episode: podcasts.apple.com/us/podcast/hea… Take a listen & join the conversation.

0

8

28

6

2.0K

Ben Derman Retweeted

c

chadi nabhan MD, MBA, FACP@chadinabhan · Jul 15

This week’s #HealthcareUnfiltered is out - all you need to know about multiple myeloma newest data from the latest Teo scientific congresses. #mmsm @bdermanmd of @UofC @UChicagoMed joins the show tackling all challenging questions in this disease. podcasts.apple.com/us/podcast/hea…

0

6

10

0

1.0K

Ben Derman Retweeted

c

chadi nabhan MD, MBA, FACP@chadinabhan · Jul 15

What are the newest advances in myeloma? ⁦@bdermanmd⁩ joins my #HealthcareUnfiltered podcast to share latest date from #ASCO25 & #EHA25. Here’s a link to the full episode: podcasts.apple.com/us/podcast/hea… Take a listen & join the conversation.

0

5

11

2

3.0K

B

Ben Derman@bdermanmd · Jul 15

Tune in to hear latest updates from ASCO and EHA in myeloma! @chadinabhan is so naturally curious and able to draw out the interesting storylines!

cchadi nabhan MD, MBA, FACP@chadinabhan · Jul 14

Tomorrow on #HealthcareUnfiltered, I host ⁦@bdermanmd⁩ of ⁦@UCCancerCenter⁩ to discuss myeloma updates from ⁦@ASCO⁩ #ASCO25 and #EHA25 Lots happening in front-line & relapsed disease - we discuss it all. Tune in tomorrow morning. Clip below.

0

2

9

1

2.0K

Ben Derman Retweeted

c

chadi nabhan MD, MBA, FACP@chadinabhan · Jul 14

Tomorrow on #HealthcareUnfiltered, I host ⁦@bdermanmd⁩ of ⁦@UCCancerCenter⁩ to discuss myeloma updates from ⁦@ASCO⁩ #ASCO25 and #EHA25 Lots happening in front-line & relapsed disease - we discuss it all. Tune in tomorrow morning. Clip below.

0

5

13

3

3.0K

Ben Derman Retweeted

M

Muzaffar Qazilbash@Transplant_Doc · Jul 12

Sequential BCMA CAR-T Cell Therapy (cilta-cel in patients relapsing after ide-cel) in RRMM. N=10, VGPR: 100%, MRD-ve: 60%. 6-month PFS: 64.8% #mmsm #bmtsm @BloodPortfolio ashpublications.org/bloodadvances/…

1

14

38

13

3.0K

Ben Derman Retweeted

T

The Lancet Haematology@TheLancetHaem · Jun 30

📢Final BELLINI results at 45.6 months follow-up show no overall survival benefit of venetoclax in the general relapsed or refractory multiple myeloma population. Post-hoc analyses suggest benefits are limited to biomarker-positive subgroups. 👇 shorturl.at/bwOYn

0

25

52

22

6.0K

Ben Derman Retweeted

A

Ajay Major, MD, MBA@majorajay · Jun 27

No more REMS for FDA-approved CAR-T products! Also, labeling updated for only 2 weeks in proximity to CAR center and 2 weeks no driving. #lymsm #tcellrx #mmsm fda.gov/vaccines-blood…

2

11

41

7

6.0K

Ben Derman Retweeted

V

Vincent Rajkumar@VincentRK · Jun 18

Just out: Guidelines for testing and reporting cytogenetic results in myeloma @BloodCancerJnl⁩ #OpenAccess Bookmark! Allows you to incorporate latest IMS/IMWG high risk criteria in practice. ⁦@lbaughn⁩ ⁦@RahulBanerjeeMD⁩ ⁦@Rfonsi1⁩ nature.com/articles/s4140…

3

54

137

70

12.0K

Ben Derman Retweeted

M

Multiple Myeloma RF@theMMRF · Jun 18

Join us in ONE week for an MMRF Patient Webinar for the latest updates in #myeloma treatment, straight from #ASCO25 and #EHA2025. 📅 June 25 🕑 1pm ET/10am PT 👨‍⚕️ @bdermanmd & @Dr_AdrianaRossi 🏥@UChicagoMed & @MountSinaiNYC @TischCancer Register now: ow.ly/z9f750W7sxJ

0

1

6

0

748

Ben Derman Retweeted

Y

Yi Lin@YiLinMDPhD · Jun 8

While many #CART centers are proficient in managing CRS & ICANS, we are all learning how best to evaluate & manage emerging late toxicities in the field. Fortunate to have @ANASTASIA_ZEK and @NavreetChowlaMD bring their team expertise. Stay tuned for updates as we learn more.

2

10

28

22

3.0K

B

Ben Derman@bdermanmd · Jun 3

A lot of studies with K-based quad induction being presented. From the IsKia trial (Isa-KRd vs KRd), with ongoing consolidation post-transplant, we see smaller differences in MRD negativity as time goes on with addition of Isa. Except for those with 2+ high-risk abnormalities.…

bdermanmd's tweet image. A lot of studies with K-based quad induction being presented.
From the IsKia trial (Isa-KRd vs KRd), with ongoing consolidation post-transplant, we see smaller differences in MRD negativity as time goes on with addition of Isa. Except for those with 2+ high-risk abnormalities.…

1

5

18

14

3.0K